Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Mr. Joaquin Duato is the Chairman of the Board of Johnson & Johnson, joining the firm since 2016.
What is the price performance of JNJ stock?
The current price of JNJ is $239.72, it has decreased 0.53% in the last trading day.
What are the primary business themes or industries for Johnson & Johnson?
Johnson & Johnson belongs to Pharmaceuticals industry and the sector is Health Care
What is Johnson & Johnson market cap?
Johnson & Johnson's current market cap is $577.0B
Is Johnson & Johnson a buy, sell, or hold?
According to wall street analysts, 27 analysts have made analyst ratings for Johnson & Johnson, including 6 strong buy, 12 buy, 14 hold, 0 sell, and 6 strong sell